Platelet lysate based dermal formulation for the treatment of skin ulcers
The LYSADERM project aims at the fabrication of a medicinal cream containing Platelet Lysate (PL), that can be used for the topical therapy of skin ulcers. The applicant company Episkey is an innovative start-up founded in 2016 with the aim of introducing into the market novel therapeutic products obtained from human Platelet Lysate. Episkey holds the exclusive licenses of international patents covering the therapeutic administration of cord blood Platelet Lysate, and already developed an international network of cord blood banks aimed at the procurement of Cord Blood Platelet Lysate for pharmaceutical transformation into platelet derivatives and drugs.  Within the broad scope of our company mission, the LYSADERM project aims at marketing a novel formulation of dermatological cream containing tissue regenerative factors present in human platelets. The LYSADERM dermatological cream will be therefore used for the treatment of skin ulcers, including serious disorders, such as diabetic foot ulcers, pressure ulcers and leg ulcers.  LYSADERM aims to be the first pharmaceutical cream containing Platelet Lysate, and it is expected to improve healing of the ulcers in comparison to conventional treatments, at lower cost; therefore, it would become the standard procedure to treat diabetic foot ulcers, pressure ulcers and leg ulcers. The LYSADERM business project is expected to generate positive outcomes for the whole society, such as the increase of effectiveness in the treatment of skin ulcers both in hospitals and at the patient’s home. It is roughly estimated that once industrialized, LYSADERM can generate in just 5 years a total of over 10 M annual revenues, covering the 0.4% of the EU market share.  Overall, the main objective of our phase I project is to achieve the technical definition of the LYSADERM product, to realize a complete exploitation plan, and to consolidate our business plan through a second-level FTO and the definition of the financial forecasts.